Skip to main content

European Infrastructure for Translational Medicine (EATRIS)

The European infrastructure for translational medicine (EATRIS) is a European infrastructure for translational medicine which allows collaboration between academics, doctors, researchers, patients, industry and decision-making bodies around Europe to facilitate and accelerate the development of medication and therapies that improve the life of people.

The platform is legally incorporated under the legal form of a non-profit European Research Infrastructure Consortium (ERIC), a legal framework specially designed to facilitate the joint establishment and operation of search infrastructures of European interest. 

The organisational model of EATRIS is based on nodes that coordinate the platform at national level. The institutions are selected from each country according to the following characteristics:

  • Background in public-private collaboration in translational development 
  • Multidisciplinary teams of academic experts 
  • High-quality research facilities

In Spain, the scientific leadership of EATRIS-ES fell on the shoulders of Dr Comella, as Director of the Vall d'Hebron Research Institute (VHIR) for 13 years and until May 2022. Currently holds the National Director position María Laura García Bermejo, from Instituto Ramón y Cajal de Investigación Sanitaria. The coordination remains a responsibility of the Carlos III Health Institute (ISCIII). The Spanish node is made up by the majority of the translational research institutes that have been approved by the ISCIII Health Research Institute. VHIR is a member, together with another twenty six approved research institutes from around the country.

With its headquarters in Amsterdam, there are currently 14 countries that form part of the EATRIS: Bulgaria, Croatia, the Czech Republic, Finland, France, Italy, Lithuania, Luxembourg, the Netherlands, Norway, Portugal, Slovenia, Sweden and Spain. They are represented by 131 research institutes, grouped into five scientific platforms: 

  • Advanced Therapeutic Medicinal Products (ATMP)
  • Biomarkers
  • Imaging & Tracing (I&T)
  • Small Molecules (SM)
  • Vaccines

EATRIS offers the following services:

  • Facilitates public-private collaboration, as well as access to cutting-edge technological facilities at the European level.
  • Provides support in research funding.
  • Offers training in key areas of translational medicine.
  • Offers assessment in regulatory matters, whether through the cooperation of member entities or its own infrastructure.